Analyst · Ionis Pharmaceuticals, Inc. (IONS) | Ratings, Price Targets & Consensus

Analyst Consensus

Buy44 analysts

Buy

Updated Jul 14, 2026

Total Analysts44

Strong Buy

1

Buy

20

Hold

12

Ratings

Updated Jul 14, 2026

Overall Rating

D+

DCF Score1.0 / 5

Debt / Equity Score1.0 / 5

Price / Book Score1.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$54.93

Median Target+62.48%

$89.25

Potential upside vs current price

Analyst Consensus

Buy44 analysts

Buy

Updated Jul 14, 2026

Total Analysts44

Strong Buy

1

Buy

20

Hold

12

Ratings

Updated Jul 14, 2026

Overall Rating

D+

DCF Score1.0 / 5

Debt / Equity Score1.0 / 5

Price / Book Score1.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$54.93

Median Target+62.48%

$89.25

Potential upside vs current price